Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326140 | 0.82 | HRH3 (0.51) | ESR1KDM4EALDH1A1LMNA | |
| SCHEMBL12586824 | 0.80 | SMPD1 (0.71) | THRATHRBPRSS1SMPD1 | |
| SCHEMBL8126769 | 0.78 | ESR1 (0.60) | CHRNB2CHRNA4ESR1KDM4EALDH1A1 | |
| SCHEMBL4846612 | 0.78 | ESR1 (0.63) | CHRNB2CHRNA4ESR1KDM4EALDH1A1 | |
| SCHEMBL6623073 | 0.78 | KMT2A (0.69) | CHRNB2CHRNA4ESR1KDM4EALDH1A1 | |
| SCHEMBL3652803 | 0.77 | ESR1 (0.61) | CHRNB2CHRNA4ESR1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL8702528 | 0.77 | KMT2A (0.68) | CHRNB2CHRNA4ESR1KDM4EALDH1A1 | |
| SCHEMBL4638666 | 0.75 | ESR1 (0.67) | CHRNB2CHRNA4ESR1KDM4EALDH1A1 | |
| SCHEMBL15131120 | 0.75 | ESR1 (0.64) | CHRNB2CHRNA4ESR1KDM4EALDH1A1 | |
| SCHEMBL4751187 | 0.75 | SMPD1 (0.44) | PRSS1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | CHRNB2 4679/4885CHRNA4 4666/4885ESR1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.